Ensifentrine
Ensifentrine (RPL-554) is an inhaled dual inhibitor of PDE3 and PDE4 with IC50s of 0.4 nM and 1479 nM, respectively. Ensifentrine blocks PDE3 and PDE4 enzymes, thereby increasing the levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) in lung cells, dilating the bronchi, and inhibiting the activation and migration of inflammatory cells. Ensifentrine can be used in the research of chronic obstructive pulmonary disease (COPD) [1][2][3].
Product Specifications
CAS Number
1884461-72-6
Product Name Alternative
RPL-554
UNSPSC
12352005
Target
Phosphodiesterase (PDE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Infection; Inflammation/Immunology; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/ensifentrine.html
Purity
99.70
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(NCCN1C(N(C2=C/C1=N\C3=C(C=C(C=C3C)C)C)CCC4=C2C=C(C(OC)=C4)OC)=O)N
Molecular Formula
C26H31N5O4
Molecular Weight
477.56
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
PDE3; PDE4
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
FITC Conjugated Vigna radiata Lectin (Mung Bean) -VRA-
